Context
A fast-growing biotech startup with a novel diagnostic platform was preparing for a Series B round.
Investors required clarity on the strength and commercial value of the IP, and the founders needed help articulating their strategy and path to commercialisation at scale.
What we did
- Assessed the company’s patent portfolio and protection strategy
- Evaluated competitor technologies and freedom-to-operate risks
- Developed a clear IP commercialisation and licensing roadmap
- Prepared investor-ready materials explaining the strategic value of the technology
Impact
The company raised its round. Investors named the IP strategy as a factor in their decision.